Term
| Which two drugs are cytosine analogs that inhibit DNA methylation at cytosine residues? |
|
Definition
Azacytidine (Vidaza)
Decitabine (Dacogen) |
|
|
Term
| Azacytidine and decitabine are approved for the treatment of ___________________ |
|
Definition
| Myelodysplastic syndrome (MDS) |
|
|
Term
| Both azacytidine and decitabine are converted to its corresponding 5'-triphosphate which is then incorporated into DNA where it blocks the action of DNA _______________ |
|
Definition
|
|
Term
| _______________ are organized into an octamer known as a _______________ around which DNA is wound |
|
Definition
|
|
Term
| Which enzyme causes acetylation of these L-amino groups reducing histone basicity, therefore exposing portions of the DNA to transcription factors which in turn leads to gene expression. |
|
Definition
| Histone acetyltransferase (HAT) |
|
|
Term
| Which class of enzymes remove the acetyl groups from the histone L-N-acetylated lysines? |
|
Definition
| Histone deacetylases (HDAC) |
|
|
Term
| ________________ is a histone deacetylase inhibitor (HDAC inhibitor) |
|
Definition
|
|
Term
| What does EGFR stand for? |
|
Definition
| Epidermal Growth Factor Receptor |
|
|
Term
| What are the two major members of the EGFR family of proteins? |
|
Definition
ErbB1 (EGF-R, HER1)
ErbB2 (HER2/neu) |
|
|
Term
| Which receptor is overexpressed in about 30% of breast cancers and because of this increased expression of the gene it correlates with poor prognosis. |
|
Definition
|
|
Term
| The HER2/neu receptor alone is the target of this monoclonal anitbody |
|
Definition
|
|
Term
| Two antineoplastic monoclonal anitbodies both target the ErbB1 receptor |
|
Definition
Cetuximab (Erbitux)
Panitumumab (Vectibix) |
|
|
Term
| Which drug inhibits the intracellular phosphorylation of the ErbB1 receptor which is overexpressed in certain lung cancers? |
|
Definition
|
|
Term
| This drug is an inhibitor of HER1 tyrosine kinase, which is associated with the epidermal growth factor receptor |
|
Definition
|
|
Term
| This drug is a dual RTK inhibitor that inhibits both ErbB1 and HER2/neu |
|
Definition
|
|
Term
| This drug is used for the treatment of advanced renal cell carcinoma |
|
Definition
|
|
Term
| This drug is an RTK inhibitor that is approved for the treatment of gastrointestinal stromal tumor (GIST) and renal cell carcinoma |
|
Definition
|
|
Term
| The VEFG receptor is another RTK. What does VEFG stand for? |
|
Definition
| Vascular Endothelial Growth Factor |
|
|
Term
| This drug targets all 3 isoforms of the VEFG receptor and is used in the treatment of renal cell carcinoma |
|
Definition
|
|
Term
| This drug which targets VEGF is approved for use with 5-FU in advanced colorectal cancer and with interferon-alpha in renal cell carincoma |
|
Definition
|
|
Term
| The chromosome translocation responsible for chronic myelogenous leukemia occurs because of an abnormal chromosome known as the ____________ chromosome |
|
Definition
|
|
Term
| The philadelphia chromosome has the N terminus of the Bcr protein joined to the C terminus of the Abl protein tyrosine kinase (PTK) and as a result the Abl kinase domain becomes _______________________ |
|
Definition
| Inappropriately (constitutively) active |
|
|
Term
| This drug was the first FDA approved drug targeted to a specific molecular defect in cancer and has been used orally in the treatment of chornic myelogenous leukemia |
|
Definition
|
|
Term
| What does mTOR stand for? |
|
Definition
| Mammalian Target of Rapamycin |
|
|
Term
| What type of kinase is mTOR? |
|
Definition
| Serine/threonine protein kinase |
|
|
Term
| Which drug is able to inhibit mTOR through association with its intracellular receptor? |
|
Definition
|
|
Term
| This mTOR inhibitor is approved for the treatment of advanced renal cell carcinoma |
|
Definition
|
|
